Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
申请人:Beutel A. Bruce
公开号:US20060178400A1
公开(公告)日:2006-08-10
The present invention relates to compounds of formula (I),
which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.
The synthesis and structure–activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: Polar region modifications
作者:Xiangdong Xu、Moshe Weitzberg、Robert F. Keyes、Qun Li、Rongqi Wang、Xiaojun Wang、Xiaolin Zhang、Ernst U. Frevert、Heidi S. Camp、Bruce A. Beutel、Hing L. Sham、Yu Gui Gu
DOI:10.1016/j.bmcl.2006.12.047
日期:2007.3
The structure-activity relationship study focused on the polar region of the HTS hit A-80040 (1) producing several series of potent and selective ACC2 inhibitors. The SAR suggests a compact lipophilic pocket that does not tolerate polar and ionic groups. Replacement of the hydroxyurea group with isoxazoles improves ACC2 selectivity while maintaining potency. Variations at the propargylic site of 11a reduce ACC2 potency. (c) 2006 Elsevier Ltd. All rights reserved.